Idexx Laboratories price target raised to $600 from $580 at Leerink

Leerink analyst Daniel Clark raised the firm’s price target on Idexx Laboratories (IDXX) to $600 from $580 and keeps an Outperform rating on the shares. The firm continues to like Idexx’s setup over the next few years and raises its 12-month price target following channel checks and its semiannual veterinarian survey.